Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006365 · ClinicalTrials.gov registry record · Phase 2
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
- 20
- Study locations
NCT00006365 is a Phase 2 study of Prostate Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 138 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00006365, a Phase 2 study of Prostate Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of external-beam radiation therapy followed by implanted radiation therapy in treating patients who have prostate cancer.
Conditions Studied
Interventions
- RADIATION radiation therapy
- RADIATION brachytherapy
- RADIATION iodine I 125
Study Locations (20)
California
- Mount Diablo Medical Center - Concord
- Cancer Center and Beckman Research Institute, City of Hope - Duarte
- California Cancer Center - Fresno
- Saint Agnes Cancer Center - Fresno
- Glendale Memorial Hospital and Health Center - Glendale
- Sutter Health West Cancer Research Group - Greenbrae
- University of California San Diego Cancer Center - La Jolla
- Loma Linda University Medical Center - Loma Linda
- Veterans Affairs Medical Center - Long Beach - Long Beach
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- Huntsville Hospital System - Huntsville
- Comprehensive Cancer Institute of Huntsville - Huntsville
- MBCCOP - Gulf Coast - Mobile
- Alabama Oncology, LLC - Montgomery
- Radiation Oncology Associates of West Alabama - Tuscaloosa
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- Arizona Cancer Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2000-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006365
The ClinicalTrials.gov registry entry for NCT00006365 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which radiation therapy is the first listed.
NCT00006365 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00006365 about?
NCT00006365 is a clinical study titled "External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of external-beam radiation therapy followed by implanted radiation therapy in treati...
What is the current status of trial NCT00006365?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2000-11. Estimated completion is 2013-11.
What conditions does trial NCT00006365 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00006365?
The interventions under investigation include: radiation therapy (RADIATION), brachytherapy (RADIATION), iodine I 125 (RADIATION).
Who is sponsoring clinical trial NCT00006365?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006365 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.